[go: up one dir, main page]

WO2003017774A1 - Composition a forte teneur lipidique au gout agreable - Google Patents

Composition a forte teneur lipidique au gout agreable Download PDF

Info

Publication number
WO2003017774A1
WO2003017774A1 PCT/GB2002/003864 GB0203864W WO03017774A1 WO 2003017774 A1 WO2003017774 A1 WO 2003017774A1 GB 0203864 W GB0203864 W GB 0203864W WO 03017774 A1 WO03017774 A1 WO 03017774A1
Authority
WO
WIPO (PCT)
Prior art keywords
composition according
composition
triglyceride
emulsifier
fat
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/GB2002/003864
Other languages
English (en)
Inventor
Carine Beysen
Keith N. Frayn
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oxford University Innovation Ltd
Original Assignee
Oxford University Innovation Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oxford University Innovation Ltd filed Critical Oxford University Innovation Ltd
Publication of WO2003017774A1 publication Critical patent/WO2003017774A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23D—EDIBLE OILS OR FATS, e.g. MARGARINES, SHORTENINGS OR COOKING OILS
    • A23D7/00—Edible oil or fat compositions containing an aqueous phase, e.g. margarines
    • A23D7/01—Other fatty acid esters, e.g. phosphatides
    • A23D7/011—Compositions other than spreads
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23D—EDIBLE OILS OR FATS, e.g. MARGARINES, SHORTENINGS OR COOKING OILS
    • A23D7/00—Edible oil or fat compositions containing an aqueous phase, e.g. margarines
    • A23D7/005—Edible oil or fat compositions containing an aqueous phase, e.g. margarines characterised by ingredients other than fatty acid triglycerides
    • A23D7/0053—Compositions other than spreads
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L27/00—Spices; Flavouring agents or condiments; Artificial sweetening agents; Table salts; Dietetic salt substitutes; Preparation or treatment thereof
    • A23L27/80—Emulsions
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/115—Fatty acids or derivatives thereof; Fats or oils
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/115—Fatty acids or derivatives thereof; Fats or oils
    • A23L33/12—Fatty acids or derivatives thereof

Definitions

  • the invention relates to a palatable orally-ingestible composition containing a high proportion of fat, which thus provides an easy way in which to provide energy in this form, and to methods of making such a composition.
  • the compositions of the invention may contain a variety of different sources of fat.
  • the invention may be used as a dietary supplement to provide a concentrated source of fat, or as a fat emulsion for special dietary use.
  • Fat like protein and carbohydrate, is a principal and essential component of the diet. At nine kilocalories per gram, fat is the most concentrated source of energy in the diet; protein and carbohydrates contribute only about four kilocalories per gram.
  • dietary fats are a source of fatty acids, including essential fatty acids that are necessary to assure the maintenance of good health. These fatty acids must be obtained from dietary sources (primarily vegetable oils), since the body cannot synthesize them itself. Fat is also responsible for transporting the fat-soluble vitamins A, D, E and K.
  • Fatty acids are classified by their structure as either saturated, monounsaturated or polyunsaturated.
  • Saturated fats are mainly found in foods of animal origin, including the fats in whole milk, cream, cheese, butter, meat and poultry. Saturated fats also can be found in large amounts in some vegetable products, such as cocoa butter, coconut oil and palm oil.
  • Monounsaturated fats are found primarily in plants, but also are found in animals. Olive, peanut and canola oil are common examples of fats that are high in monounsaturated fatty acids.
  • Polyunsaturated fats are found mostly in plants. Sunflower, corn, soybean, cotton seed and safflower oils are vegetable fats that contain a relatively high proportion of polyunsaturated fats.
  • lipid emulsions that contain long chain triglycerides (LCT emulsions) that are delivered parenterally.
  • LCT emulsions lipid emulsions that contain long chain triglycerides
  • Parenteral delivery requires a degree of technical support (so increasing the burden on health services) and generally prevents such patients being treated at home.
  • Certain pathological conditions, such as anaemia, also require a patient to intake supplemental dietary fat.
  • a composition termed Calogen (SHS) is an emulsion consisting of long chain triglycerides (LCT) from highly refined peanut oil. This composition may be used as a dietary supplement to provide a concentrated source of fat in the form of long chain triglycerides. However, this composition is limited to the delivery of peanut oil and does not allow the delivery of any kind of specific triglyceride.
  • a second composition, termed Microlipid® is a 50% fat emulsion for special dietary use in oral or tube-feeding formulas, that may be mixed into enteral formulas, beverages, and table food. This composition includes safflower oil (a rich source of polyunsaturated fats). Again, the technology used to produce Microlipid® does not allow the generation of a composition that can be adjusted for different fat contents.
  • a palatable ingestible composition for the oral delivery of fat, said composition comprising a) a triglyceride component in a proportion of at least about 20% w/w; b) an emulsifier component consisting of a partial glyceride; c) a flavouring agent; and d) an aqueous solvent.
  • compositions of the invention are palatable, meaning that the invention does not suffer the drawbacks of currently available fat compositions. There is no product currently available that provides a composition with fat as the major energy source and which focuses on the composition of the fat. Furthermore, the compositions of the invention may be modified so as to incorporate any type of triglyceride.
  • triglyceride is used herein to refer to fats that may be used in the compositions of the invention.
  • saturated fatty acids are very hard to emulsify and are therefore difficult to incorporate into a composition in high proportions.
  • the compositions of the invention may be designed so as to emulsify saturated fatty acids in high proportions (up to 50% and above).
  • compositions of the invention inco ⁇ orate high proportions of triglyceride.
  • the proportion of triglyceride in the compositions according to the invention may be greater than 20% w/w, preferably, greater than 30%, more preferably, greater than 40%, even more preferably, 45%, most preferably, 50% or more.
  • Suitable triglycerides may be composed of saturated fatty acids (for example, myristic acid, palmitic acid and stearic acid), monounsaturated fatty acids (for example, palmitoleic acid and oleic acid), polyunsaturated fatty acids (for example, linoleic acid, linolenic acid, arachidonic acid and n-3 polyunsaturated acids), trans-unsaturated fatty acids, omega-3 fatty acids, trans fatty acids, or a mixture of one or more of these triglycerides.
  • saturated fatty acids for example, myristic acid, palmitic acid and stearic acid
  • monounsaturated fatty acids for example, palmitoleic acid and oleic acid
  • polyunsaturated fatty acids for example, linoleic acid, linolenic acid, arachidonic acid and n-3 polyunsaturated acids
  • trans-unsaturated fatty acids omega-3 fatty acids, trans
  • the invention is of particular utility with respect to the use of high proportions of saturated fatty acids, such as palmitic and stearic acids, which are very difficult to emulsify and are thus very difficult to administer in high quantities.
  • saturated fatty acids such as palmitic and stearic acids
  • Such triglycerides cannot presently be delivered parenterally or orally.
  • an emulsifier component In order to emulsify the triglyceride into a homogenous emulsion, an emulsifier component must be included in the composition of the invention.
  • the emulsifier component should include a partial glyceride or combination of partial glycerides. This component has been found to be particularly effective in emulsifying triglycerides, particularly those composed of saturated fatty acids, in a high percentage proportion into aqueous solution.
  • the partial glyceride should be a monoglyceride or diglyceride or derivative thereof.
  • a suitable source of partial glyceride is cocoa powder, which, in addition to protein and carbohydrate, contains a number of species of partial glyceride.
  • a partial glyceride emulsifying agent known as HYMONO 8903K emulsifier (Quest International) has been found by the inventors to be particularly suitable for use in preparing compositions according to the invention.
  • the emulsifier component should be present in the compositions of the invention in an amount sufficient to emulsify the amount of triglyceride that is intended to be used in the composition.
  • the emulsifier component is more costly than the other components of the compositions of the invention, meaning that its use should ideally be restricted to the minimum amount that is necessary to emulsify the triglyceride.
  • the proportion of emulsifier used will also vary dependent on the efficacy of the emulsifier used.
  • the proportion of the emulsifier component should be between 0.1 % and 5% w/w.
  • a composition according to the invention contains between 0.5% and 1 % emulsifier, more preferably, around 0.5%.
  • compositions of the invention should also contain a flavouring agent.
  • a flavouring agent increases the palatability of the composition, so facilitating its ingestion and imparting a pleasant taste to the composition.
  • the compositions of the invention taste rather pleasant, in contrast to high fat compositions that have been prepared previously, which induce nausea and even vomiting.
  • cocoa powder has a potent activity as an emulsifier, and at the same time imparts a pleasant flavour. Cocoa powder is thus an example of a preferred flavouring agent according to the invention.
  • the choice of flavouring agent may differ depending on the individual or the organism for which the composition is intended.
  • the flavouring agent may not be a sweetener, but may impart a savoury taste (such as fish oil for cats, or meat flavour for dogs).
  • a savoury taste such as fish oil for cats, or meat flavour for dogs.
  • sweeteners will generally be a component of the preferred flavouring agent, optionally in combination with cocoa powder, for example, to impart a chocolate flavour to the composition.
  • sweeteners include Hermesetas granulated sweetener, saccharin and aspartame. Other examples will be clear to those of skill in the art.
  • the final ingredient of the compositions according to the invention is the solvent, which should be an aqueous solvent.
  • Suitable aqueous solvents include water, an aqueous electrolyte solution or an aqueous-alcoholic solvent.
  • the solvent used is water.
  • the compositions of the invention may be used in a number of different ways.
  • the compositions may be used as dietary supplements to provide energy in the form of fat.
  • this strategy is very different from the cunent goals of most food manufacturers, who, in view of the weight conscious public to whom they sell, aim to reduce the fat content of their products as much as possible.
  • compositions of the invention may be sold as nutritional supplements, particularly for individuals who participate in active or endurance sports, or those participating in expeditions, such as polar expeditions, or polar research.
  • Some endurance athletes may need to consume 4,000-6,000 kilocalories/day to maintain energy balance, particularly in long distance events such as ultra-marathons, long distance bicycle rides such as the Tour de France and adventure races. Daily fat consumption makes a significant contribution in meeting these energy needs.
  • evidence has shown that increasing energy intake after exercise, while the athlete is resting, facilitates recovery and is likely to improve repeat performances that must be attempted within a short period of time. This is particularly important in endurance events that continue over a number of days (Saris W.H.M., Limits of human endurance: lessons from the Tour de France.
  • compositions of the invention allow such a significant fat intake without requiring the ingestion of a large amount of food. Ingesting small amounts of concentrated fat in this manner may also enhance the amount of triglyceride stored and increase the rate of its storage.
  • compositions of the invention might be used to enhance the fat uptake of particular animal populations, such as domesticated livestock intended for human consumption. It may be that the flavour of the animal meat or its fatty acid composition may be altered beneficially, or that the weight or growth rate of the animal may be increased in order to reduce the cost of raising livestock.
  • This aspect of the invention thus provides a method for enhancing the fat uptake of an animal comprising administering to the animal a palatable ingestible composition according to any one of the embodiments of the invention described above.
  • compositions of the invention may also be used as a dietary source to deliver specific fatty acids to an individual. This may be useful to address specific deficiencies suffered by individuals. For instance, essential fatty acid deficiency has been suggested to underlie attention-deficit/ hyperactivity disorder (Stevens et al, 1995, Am J Clin Nutr: 62: 761 -8) and dyslexia; pre-term infants deprived of vital fatty acids during late pregnancy are likely to have failures of normal development, especially development of the visual system, if not provided with dietary supplements of omega-3 fatty acids (Innis, 1992, Lipids, 27(1 1 ): 879-887); higher palmitic and lower omega-3 fatty acids in serum are correlated with higher incidence of coronary heart disease in middle-aged men at high risk for cardiovascular disease (Simon et al, 1995, Stroke, 26: 778-82); changes in dietary fatty acid intake cause alterations in immune response, including anti-tumor activity (Erikson et al, 1995, J
  • compositions of the invention as a dietary source may also maximize the nutritional value that the compositions may provide.
  • This aspect of the invention thus provides a method for treating a disorder relating to a fatty acid deficiency in a patient, said method comprising administering to the patient a palatable ingestible composition according to any one of the embodiments of the invention described above.
  • the compositions of the invention may also be used as tools for human and animal research to increase specific fatty acids in the circulation and to test for the effect of this manipulation on physiology. In this manner, the effects of particular fatty acids on metabolism may be assessed, not only for healthy individuals, but also for individuals who are severely overweight or underweight.
  • the metabolic effect of ingesting too much or too little fat, or too much or too little of a specific type of fat may be assessed and the types of fatty acid that are beneficial or detrimental to health can be evaluated rationally.
  • These effects may also be evaluated for diseased individuals, such as those suffering from diabetes, and the metabolic patterns found in diseased and healthy individuals can be compared.
  • the compositions of the invention allow a researcher to be able to alter the dietary intake of fats in such individuals, as desired.
  • compositions of the invention have an acceptable shelf-life, in that they can be stored refrigerated or at room temperature for a significant period of time and reconstituted by brief shaking before use.
  • This is a further advantage of the compositions of the present invention in that no specialized equipment or refrigeration is required to store the compositions. This means, for example, that the compositions may be sold to the public at normal grocer-type outlets and will not need to be prepared upon demand by dispensing chemists.
  • compositions of the invention may also be freeze-dried.
  • Granules of freeze-dried composition may then be reconstituted when required, for example, using warm water and stirring vigorously.
  • Such freeze-dried or lyophilised compositions form a further aspect of the invention.
  • a method of preparing a palatable ingestible composition comprising the steps of: a) combining the triglyceride and emulsifier components and warming the mixture until the emulsifier component has melted into the oil; b) adding the flavouring agent to the solution of triglyceride and emulsifier components; c) slowly mixing the solvent into the composition whilst stirring continuously; d) blending the final composition together to form an emulsion.
  • the method is performed in the order of steps recited above.
  • step a the triglyceride and emulsifier components are combined and the mixture is warmed, generally to around 65-70°C, when the emulsifier component will gradually melt into the oil.
  • the temperature to which the mixture is raised will depend upon the type of triglyceride that is to be incorporated into the composition. For example, saturated fats are usually solid at room temperature, whilst monounsaturated fats are liquid and polyunsaturated fats are usually liquid at room temperature.
  • the melting temperature may thus need to be increased above 70°C for compositions that incorporate a large amount of saturated triglyceride. The temperature should be kept well below boiling point.
  • flavouring agent should then be mixed into the solution of triglyceride and emulsifier components.
  • the next step is the incorporation of the aqueous solvent into the composition. This should be done very slowly, with the solution being mixed continuously while the solvent is being inco ⁇ orated. Finally, the resulting composition is blended together to form an emulsion. This may be performed using any of a number of techniques, as the skilled reader will be aware. In the case of a small-scale laboratory process, a hand-mixer may be used, homogenizing the composition for around two minutes.
  • Figure 1 shows specific fatty acid composition during a test with olive oil in which small portions of the high fat emulsion are used to produce continuous absorption of the fat of interest (as triglycerides) accompanied by a slow infusion of heparin, a substance to activate the enzyme lipoprotein lipase;
  • Figure 2 shows specific fatty acid composition during safflower oil test
  • Figure 3 shows specific fatty acid composition during palm stearin test.
  • Palm stearin (Anglia Oils Limited, King George Dock, Hull) for enrichment in palmitic acid in plasma
  • Cadbury's Cocoa powder (322 kcal, 23.1 g protein, 10.5 g carbohydrates, 20.8 g fat)
  • Hermesetas granulated sweetener Bottled still water
  • compositions of the invention have been tested for palatability and absorption in man.
  • Three different compositions have been used as research tools to increase specific fatty acids in the circulation in man. This was achieved by feeding small portions of the high fat emulsion to produce continuous abso ⁇ tion of the fat (as triglycerides) of interest accompanied by a slow infusion of heparin, a substance to activate the enzyme lipoprotein lipase. This enzyme hydrolyses the absorbed triglycerides in the circulation into smaller components, non-esterified fatty acids (NEFA).
  • NEFA non-esterified fatty acids
  • Figure 1 shows the increase in linoleic acid in plasma from eight volunteers when linoleic acid was the main fatty acid used in the composition.
  • Figure 2 shows the increase of mainly palmitic acid in plasma when palmitic acid was the main fatty acid used in the composition.
  • Figure 3 shows the increase in plasma oleic acid when oleic acid was the main fatty acid used in the composition.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Health & Medical Sciences (AREA)
  • Nutrition Science (AREA)
  • Mycology (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

L'invention concerne une composition au goût agréable, ingérable par voie orale, qui contient une forte teneur lipidique, ce qui permet de procurer aisément de l'énergie sous cette forme. L'invention concerne par ailleurs des procédés permettant de produire une telle composition. Les compositions selon l'invention peuvent contenir une variété de différentes sources de lipides. L'invention peut s'utiliser comme supplément diététique pour fournir une source concentrée de lipides ou comme émulsion lipidique à usage diététique particulier.
PCT/GB2002/003864 2001-08-22 2002-08-22 Composition a forte teneur lipidique au gout agreable Ceased WO2003017774A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0120415.5A GB0120415D0 (en) 2001-08-22 2001-08-22 Palatable high fat composition
GB0120415.5 2001-08-22

Publications (1)

Publication Number Publication Date
WO2003017774A1 true WO2003017774A1 (fr) 2003-03-06

Family

ID=9920816

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2002/003864 Ceased WO2003017774A1 (fr) 2001-08-22 2002-08-22 Composition a forte teneur lipidique au gout agreable

Country Status (2)

Country Link
GB (1) GB0120415D0 (fr)
WO (1) WO2003017774A1 (fr)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008063323A3 (fr) * 2006-10-13 2008-12-31 Reliant Pharmaceuticals Inc Traitement à base d'anti-arythmisants et d'acides gras oméga-3 et produit mixte obtenu à partir de ceux-ci
WO2011057731A1 (fr) * 2009-11-10 2011-05-19 Cognis Ip Management Gmbh Composition comprenant un lipide approprié à la consommation humaine
CN102264246A (zh) * 2008-10-24 2011-11-30 N.V.努特里奇亚 液体高脂肪蛋白组合物
EP2775862B1 (fr) 2011-11-07 2016-09-28 Nestec S.A. Stabilisation d'émulsion

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3851070A (en) * 1971-06-28 1974-11-26 Procter & Gamble High nutrition food spreads
US4199608A (en) * 1977-11-30 1980-04-22 Scm Corporation Low calorie containing imitation dairy products
WO1992009209A1 (fr) * 1990-11-23 1992-06-11 Unilever N.V. Utilisation de phases mesomorphes dans les produits alimentaires
EP0563593A1 (fr) * 1992-03-02 1993-10-06 Kao Corporation Emulsion type huile dans l'eau pour crème fouettée respectivement poudre de crème fouettée
EP0609465A1 (fr) * 1992-08-21 1994-08-10 Fuji Oil Company, Limited Creme patissiere

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3851070A (en) * 1971-06-28 1974-11-26 Procter & Gamble High nutrition food spreads
US4199608A (en) * 1977-11-30 1980-04-22 Scm Corporation Low calorie containing imitation dairy products
WO1992009209A1 (fr) * 1990-11-23 1992-06-11 Unilever N.V. Utilisation de phases mesomorphes dans les produits alimentaires
EP0563593A1 (fr) * 1992-03-02 1993-10-06 Kao Corporation Emulsion type huile dans l'eau pour crème fouettée respectivement poudre de crème fouettée
EP0609465A1 (fr) * 1992-08-21 1994-08-10 Fuji Oil Company, Limited Creme patissiere

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008063323A3 (fr) * 2006-10-13 2008-12-31 Reliant Pharmaceuticals Inc Traitement à base d'anti-arythmisants et d'acides gras oméga-3 et produit mixte obtenu à partir de ceux-ci
CN102264246A (zh) * 2008-10-24 2011-11-30 N.V.努特里奇亚 液体高脂肪蛋白组合物
WO2011057731A1 (fr) * 2009-11-10 2011-05-19 Cognis Ip Management Gmbh Composition comprenant un lipide approprié à la consommation humaine
EP2775862B1 (fr) 2011-11-07 2016-09-28 Nestec S.A. Stabilisation d'émulsion
US11006651B2 (en) 2011-11-07 2021-05-18 Societe Des Produits Nestle S.A. Emulsion stabilization method
US11213042B2 (en) 2011-11-07 2022-01-04 Societe Des Produits Nestle S.A. Chocolate product with cocoa particles as the emulsifying agent

Also Published As

Publication number Publication date
GB0120415D0 (en) 2001-10-17

Similar Documents

Publication Publication Date Title
JP4555471B2 (ja) ストレスにより誘発された免疫抑制を低減する製品および方法
ES2478869T3 (es) Composición nutricional enteral líquida adecuada para alimentación por sonda
EP0482715B1 (fr) Composition nutritionnelle
CA2234398C (fr) Composition nutritive pour diabetiques et methode d'obtention
US8178487B2 (en) Method for providing glutamine
KR970005330B1 (ko) 사람 면역 결핍 바이러스에 감염된 사람에 대한 영양 제품
EP1662905A1 (fr) Systeme lipidique et ses procedes d'utilisation
JPS6236645B2 (fr)
SE536599C2 (sv) Näringssammansättning med lågt kalori- och lågt proteininnehåll
JPH08322509A (ja) 多様性組成物形態の栄養素供給方法
US20170196229A1 (en) Nutritional composition
CA2978949A1 (fr) Aliment nutritif optimise
WO2018008715A1 (fr) Composition alimentaire sous forme de gel et aliment utilisant ladite composition alimentaire sous forme de gel
CN105188411A (zh) 增强dha和其它脂溶性营养物的生物利用度的方法
JP2000135070A (ja) 嚥下困難者用粉末栄養組成物
EP0388237A2 (fr) Produit diététique
WO2003017774A1 (fr) Composition a forte teneur lipidique au gout agreable
WO2016010101A1 (fr) Aliment émulsifié sous forme de gel
JPH08169824A (ja) 小児科脂質乳剤
RU2463800C2 (ru) Сухой специализированный белково-углеводный продукт для питания спортсменов
JP3886063B2 (ja) 栄養組成物
EA026141B1 (ru) Инстантный функциональный пищевой продукт
JPWO2002094039A1 (ja) 蛋白質・エネルギー低栄養状態改善用飲食物
JPS61135572A (ja) 経腸用脂肪乳剤
JPH03290166A (ja) 栄養組成物

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BY BZ CA CH CN CO CR CU CZ DE DM DZ EC EE ES FI GB GD GE GH HR HU ID IL IN IS JP KE KG KP KR LC LK LR LS LT LU LV MA MD MG MN MW MX MZ NO NZ OM PH PL PT RU SD SE SG SI SK SL TJ TM TN TR TZ UA UG US UZ VC VN YU ZA ZM

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ UG ZM ZW AM AZ BY KG KZ RU TJ TM AT BE BG CH CY CZ DK EE ES FI FR GB GR IE IT LU MC PT SE SK TR BF BJ CF CG CI GA GN GQ GW ML MR NE SN TD TG

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP